Overview

Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Genhouse Bio Co., Ltd.